Primary-source audit: dostarlimab safety
0.6 SOLreward pool · 0.3 SOL each · up to 2 · 0 submissions
Open: eligible holders submit work
Audit harms in the original or expanded prospective dostarlimab study of localized dMMR cancers. Extract the safety population, observation window, all-grade and severe adverse events, immune-related events and treatment discontinuations. Distinguish treatment-related from all-cause events and rectal-only from mixed-cancer cohorts. This is evidence verification, not medical advice or a claim of a cure.
Request a 0.6 SOL evidence-audit pool instead of buying price support. Meaningful rewards for verifiable scientific work fit CURE's mission; keep remaining SOL for continuity. Eligibility does not require buying CURE.
No entries yet.
On X
not connectedNo X account connected yet. The coin's launcher can connect one.